Apply to join a small cohort of BD, strategy, and investment people in biopharma. You get the data behind each Intel Hub report, you can ask questions of the analysts who wrote it, and you can compare notes with peers.
T-cell engagers intelligence report, Q3 2026
Autoimmune went from no deals before 2024 to the field’s busiest new lane.
Autoimmune programs
Program
Target
Lead indication
Highest stage
mosunetuzumab
CD20
SLE
Phase 2
Cizutamig
BCMA
Myasthenia gravis
Phase 1
CND261
CD20
Rheumatoid arthritis
Phase 1/2
Gamgertamig
BCMA
Autoimmune cytopenias
Phase 1/2
Every Intel Hub report stays free to read. Members also get the Excel workbook behind each deep dive, with the programs and deals under every chart. Members see each new data explorer before it goes public.
Q3 2026 Report Series
Sheets in the members’ workbook
Protein degraders
RNA
T-cell engagers
Radiopharma
In-vivo cell therapy
I&I
GLP-1 and metabolic
ADC
Each new report gets its own thread in your cohort’s channel, where the analysts who built it answer questions. It’s the same team that builds the reports and delivers Sleuth’s Concierge projects.
Ask what they counted, what they left out, and why a chart looks the way it does.
Each thread opens with the report’s predictions for the future, so you can debate the team and your peers.
Tell them the question on your desk. It can shape what they analyze next.
Members join in small cohorts, so you know who you’re talking to. You’re placed with BD, strategy, and investment people working on questions like yours.
Each cohort has its own private channel. Other cohorts can’t read it, and new members join the next cohort instead of crowding yours.
People at biotechs and pharma companies, plus the investors, bankers, and consultants who work with them, from the US, Europe, and Asia.
Beyond each report’s thread, members share news and deals, and find each other at conferences.
Membership is free, and you don’t need a Sleuth account. We read every application and invite you to the cohort that fits.
Who it’s for
BD, corporate strategy, and competitive intelligence at biotech and pharma companies
Investors, bankers, and consultants who work on biopharma
How it works
1
Apply with your work email
2
Sleuth reviews your application
3
You’re invited to your cohort’s Slack channel, with the workbooks unlocked